Featured Research

from universities, journals, and other organizations

Breakthrough? Study Finds Dopamine Cannot Be Source Of Pleasure In Brain

Date:
March 4, 1999
Source:
University Of North Carolina At Chapel Hill
Summary:
Dopamine, a chemical messenger believed for more than two decades to be the end point of the brain's pleasure system, appears not to be that molecular reward after all, a new study shows. The University of North Carolina at Chapel Hill study suggests instead that dopamine plays an early central role in pleasure, but another chemical -- possibly serotonin -- actually rings the chimes for humans and animals alike.

CHAPEL HILL - Dopamine, a chemical messenger believed for more than two decades to be the end point of the brain's pleasure system, appears not to be that molecular reward after all, a new study shows.

The University of North Carolina at Chapel Hill study suggests instead that dopamine plays an early central role in pleasure, but another chemical -- possibly serotonin -- actually rings the chimes for humans and animals alike.

Researchers say their discovery should become important in the search for solutions to substance abuse and addiction problems, researchers say.

A report on the findings appears in the March 4 issue of the journal Nature. Authors are Drs. Paul A. Garris, a postdoctoral fellow at UNC-CH now at Illinois State University, and R. Mark Wightman, William Rand Kenan Jr. professor of chemistry at UNC-CH. Others are Michaux Kilpatrick, an M.D.-Ph.D. student in Wightman's laboratory; Dr. Melissa A. Bunin, a former graduate student doing postdoctoral work in Australia; graduate student Daren Michael, and Dr. David Walker, now a Duke University postdoctoral scientist.

In what the journal dubbed "something of a technical tour de force," the studies first involved developing a carbon fiber electrode one tenth the thickness of a human hair and coating it with glass.

"When implanted in rat brains, this micro-sensor allows us for the first time to measure very small amounts of chemical messengers, or neurotransmitters, on a split-second time scale," Wightman said. "That was not possible before."

Using their device coupled with electronic equipment, Wightman and his students can record what happens inside the brain as neurotransmitters such as dopamine interact with one another in real time. They incorporated into the work experiments pioneered by Canadian researchers in which rats quickly learn that by pressing a lever, they can receive a tiny but pleasurable shock to their brain through deep probes implanted there.

"We discovered that when we applied the electric shock to untrained rats, we clearly saw dopamine, but when the animals themselves applied the shock, little or no dopamine appeared," Wightman said. "Considering that scientists have been pretty satisfied that dopamine was the important thing, this was a big surprise."

Dopamine may be involved in learning or anticipation of reward, he said. It clearly is not responsible for continuous pleasure, however, or the chemists would have detected a lot of it when trained rats repeatedly pressed the lever, too.

The new work promises better explanations of how such abused chemicals as nicotine, alcohol, cocaine and amphetamines act in the brain, Wightman said. It also might help identify less toxic substances that could ease withdrawal and make it more successful.

"Because nobody ever had a way of making these kinds of measurements, we think this is really a big jump ahead," he said. "Often it is new technology that in fact drives new findings in science and medicine."

The National Institute of Drug Abuse and the National Institute of Neurological Disorders and Stroke supported the continuing studies. A feature on the work in Wightman's laboratory will appear in April in "Endeavors," UNC-CH's research magazine.


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "Breakthrough? Study Finds Dopamine Cannot Be Source Of Pleasure In Brain." ScienceDaily. ScienceDaily, 4 March 1999. <www.sciencedaily.com/releases/1999/03/990304052313.htm>.
University Of North Carolina At Chapel Hill. (1999, March 4). Breakthrough? Study Finds Dopamine Cannot Be Source Of Pleasure In Brain. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/03/990304052313.htm
University Of North Carolina At Chapel Hill. "Breakthrough? Study Finds Dopamine Cannot Be Source Of Pleasure In Brain." ScienceDaily. www.sciencedaily.com/releases/1999/03/990304052313.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins